


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 020167-000130US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



On November 5, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Marta Vanegas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Zhong-Ru GAN

Application No.: 10/054,873

Filed: January 22, 2002

For: CHIMERIC PROTEIN
CONTAINING AN
INTRAMOLECULAR CHAPERONE-
LIKE SEQUENCE

Examiner: Not yet assigned

Art Unit: 1647

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/423,100, filed December 11, 2000 (Attorney Docket No. 020167-000120US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895

FJM:ath:mrsv



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 4

C m p l e i f K n w n

Application Number	10/054,873
Filing Date	January 22, 2002
First Named Inventor	Zhong-Ru Gan
Art Unit	1647
Examiner Name	Not yet assigned
Attorney Docket Number	020167-000130US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1	US-4,342,832	08/03/1982	Goeddel et al.	
	2	US-4,916,212	04/10/1990	Markussen et al.	
	3	US-5,254,463	10/19/1993	de Boer et al.	
	4	US-5,358,857	10/25/1994	Stengelin et al.	
	5	US-5,422,110	06/06/1995	Potter et al.	
	6	US-5,473,049	12/05/1995	Obermeier et al.	
	7	US-5,559,128	09/24/1996	Chakrabarty et al.	
	8	US-5,719,021	02/17/1998	Inouye	
	9	US-6,001,604	12/14/1999	Hartman et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	10	EP	0 055 945	A2	07/14/1982	Genentech, Inc.		<input type="checkbox"/>
	11	EP	0 347 781	B1	02/16/1994	Hoechst Aktiengesellschaft		<input type="checkbox"/>
	12	EP	0 645 454	A2	03/29/1995	Lunin et al.		<input type="checkbox"/>
	13	WO	96/20724	A1	07/11/1996	Bio-Technology General Corp.		<input type="checkbox"/>
	14	WO	96/23888	A1	08/08/1996	G.D. Searle & Co.		<input type="checkbox"/>
	15	WO	97/18233	A1	05/22/1997	Pharmacia & Upjohn AB		<input type="checkbox"/>
	16	WO	02/079251	A2	10/10/2002	Novo Nordisk A/S		<input type="checkbox"/>


Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of 4

Complete if Known

Application Number	10/054,873
Filing Date	January 22, 2002
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	Not yet assigned
Attorney Docket Number	020167-000130US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	17	BIOSIS DATABASE, Accession number 199497237023. Samuelsson <i>et al.</i> , 1994, "Enhanced <i>in vitro</i> refolding of insulin-like growth factor I using a solubilizing fusion partner," <i>Biochemistry</i> 33(14):4207-4211 (abstract)	
	18	BIOSIS DATABASE, Accession number PREV199799785120. Klappa <i>et al.</i> , 1997, "Interactions between protein disulphide isomerase and peptides," <i>European Journal of Biochemistry</i> 248(1):37-42 (abstract)	
	19	Bork and Bairoch, 1996, "Go hunting in sequence databases but watch out for the traps," <i>Trends Genet.</i> 12(10):425-427	
	20	Bork, P., 2000, "Powers and pitfalls in sequence analysis: the 70% hurdle," <i>Genome Res.</i> 10(4):398-400	
	21	Brenner, S.E., 1999, "Errors in genome annotation," <i>Trends Genet.</i> 15(4):132-133	
	22	Burgess, "Protein Purification," in <i>Protein Engineering</i> ; Oxender, D.L., Fox, C.F., Eds.; Alan R. Liss, Inc; NY, (1987), pp. 71-82.	
	23	Burnett, J. P., "Commercial Production of Recombinant DNA-Derived Products," in <i>Experimental Manipulation of Gene Expression</i> , Academic Press, NY, (1983), pp. 259-277.	
	24	Castellanos-Serra <i>et al.</i> , 1996, "Expression and folding of an interleukin-2-proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C-peptide and the N-terminal fused sequence," <i>FEBS Letters</i> , 378:171-176.	
	25	Chance <i>et al.</i> , "Chemical, Physical, and Biological Properties of Recombinant Human Insulin," in J. L. Gueriguian <i>Insulins, Growth Hormone, and Recombinant DNA Technology</i> , Raven Press, NY, (1981), pp. 71-85.	
	26	Chance <i>et al.</i> , "The Production of Human Insulin Using Recombinant DNA Technology and a New Chain Combination Procedure," in <i>Peptides: Synthesis-Structure-Function</i> , Pierce Chem. Co., Rockford, IL, (1981), pp. 721-728.	
	27	Diers <i>et al.</i> , "Yeast Fermentation Processes for Insulin Production," in Y. H. Chiu, <i>Drug Biotechnology Regulations: Scientific Basis and Practices</i> , Marcel Dekker, Inc., NY, (1991), pp. 166-176.	
	28	Doerks <i>et al.</i> , 1998, "Protein annotation: detective work for function prediction," <i>Trends Genet.</i> 14(6):248-250	
	29	Etienne-Decent, "Regulation of Protein Synthesis," in <i>Genetic Biochemistry: From Gene to Protein</i> , Ellis Horwood Limited, Chichester, U.K., (1988), pp. 125-127.	
	30	Frank and Chance, "The Preparation and characterization of human insulin of recombinant DNA origin," in <i>Therapeutic Agents Produced by Genetic Engineering "Quo Vadis?" Symposium</i> , (May 29-30, 1985), Sanoff Group, Toulouse-Labège, France, pp. 137-148.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

59059901 v1



PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Applicati n Number	10/054,873		
		Filing Date	January 22, 2002		
		First Named Inventor	Gan, Zhong-Ru		
		Art Unit	1647		
		Examiner Name	Not yet assigned		
Page	3	of	4	Attorney Docket Number	020167-000130US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	31	Frank and Chance, 1983, "Two Routes for Producing Human Insulin Utilizing Recombinant DNA Technology," <i>Munch. Med. Wschr.</i> 125(Suppl. 1):pp. S14-S20.	
	32	Goeddel <i>et al.</i> , 1979, "Expression in <i>Escherichia coli</i> of chemically synthesized genes for human insulin," <i>Proc. Natl. Acad. Sci. USA</i> 76(1): 106-110.	
	33	Ikehara <i>et al.</i> , 1984, "Synthesis of a gene for human growth hormone and its expression in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 81:5956-5960.	
	34	Inouye, M., 1991, "Intramolecular Chaperone: The Role of the Pro-Peptide in Protein Folding," <i>Enzyme</i> 45:314-321.	
	35	Johnson, 1983, "Human Insulin from Recombinant DNA Technology," <i>Science</i> 219:632-637.	
	36	Johnson, R. D., 1986, "The Processing of Biomacromolecules: A Challenge for the Eighties," <i>Fluid Phase Equilib.</i> , 29:109-123.	
	37	Kroeff <i>et al.</i> , 1989, "Production Scale Purification of Biosynthetic Human Insulin by Reversed-Phase High-Performance Liquid Chromatography," <i>Journal of Chromatography</i> 461: 45-61.	
	38	Ladisich and Kohlmann, 1992, "Recombinant Human Insulin," <i>Biotechnol. Prog.</i> 8:469-478.	
	39	Ngo <i>et al.</i> , "Computational complexity, protein structure prediction, and the Levinthal Paradox," In: <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz and Le Grand, eds. Birkhauser, Boston, MA, 1994, pp. 433-506.	
	40	Norman and Litwack, "Pancreatic Hormones: Insulin and Glucagon," in <i>Hormones</i> , Academic Press, Inc., NY, (1987), pp 264-317.	
	41	Shinde and Inouye, 1993, "Intramolecular chaperones and protein folding," <i>TIBS</i> 18:442-446.	
	42	Skolnick and Fetrow, 2000, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18(1):34-39	
	43	Smith and Zhang, 1997, "The challenges of genome sequence annotation or 'the devil is in the details,'" <i>Nat. Biotechnol.</i> 15(12):1222-1223	
	44	Thim <i>et al.</i> , 1986, "Secretion and processing of insulin precursors in yeast," <i>Proc. Natl. Acad. Sci. USA</i> 83:6766-6770.	
Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
59059901 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

4

of

4

Compleat if Kn wn

Application Number	10/054,873
Filing Date	January 22, 2002
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	Not yet assigned
Attorney Docket Number	020167-000130US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	45	Tottrup and Carlsen, 1990, "A Process for the Production of Human Proinsulin in <i>Saccharomyces cerevisiae</i> ," <i>Biotechnol. Bioeng.</i> 35:339-348.	
	46	Villa-Komaroff <i>et al.</i> , 1978, "A bacterial clone synthesizing proinsulin," <i>Proc. Natl. Acad. Sci. USA</i> 75(8):3727-3731.	
	47	Watson <i>et al.</i> , <i>Recombinant DNA—A Short Course</i> , Scientific American Books, W.H. Freeman Co., NY, (1983), pp. 231-241.	
	48	Wells, J. A., 1990, "Additivity of mutational effects in proteins," <i>Biochemistry</i> 29(37):8509-8517	
	49	Wheelwright, <i>Protein Purification: Design and Scale up of Downstream Processing</i> , Oxford University Press; NY, (1991), p.217.	
	50	Williams <i>et al.</i> , 1982, "Cytoplasmic Inclusion Bodies in <i>Escherichia coli</i> Producing Biosynthetic Human Insulin Proteins," <i>Science</i> 215:687-689.	

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


GP1647

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

Use for all correspondence after initial filing)

Application Number		10/054,873
Filing Date		January 22, 2002
First Named Inventor		Gan, Zhong-Ru
Art Unit		1647
Examiner Name		Not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number 020167-000130US	

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP	
	Frank J. Mycroft	Reg. No. 46,946
Signature		
Date	November 5, 2003	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Marta R. Vanegas		
Signature		Date	November 5, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.